Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 6/20 | 0.34 |
| ▸ | CNR2 | P34972 | 3/20 | 0.34 |
| ▸ | SLC5A1 | P13866 | 5/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.32 |
| ▸ | RORA | P35398 | 1/20 | 0.32 |
| ▸ | RORC | P51449 | 1/20 | 0.32 |
| ▸ | RORB | Q92753 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13423949 | 0.94 | CNR1 (0.36) | NR3C2CNR1CNR2SLC5A1ALDH1A1 | |
| SCHEMBL15477978 | 0.89 | NR3C2 (0.34) | NR3C2SLC5A1ALDH1A1C5AR1NR1I2 | |
| SCHEMBL13423961 | 0.89 | SLC5A1 (0.35) | NR3C2CNR1CNR2SLC5A1ALDH1A1 | |
| SCHEMBL13423956 | 0.86 | ALDH1A1 (0.46) | CNR1CNR2ALDH1A1SMN1; SMN2 | |
| SCHEMBL15477982 | 0.85 | MALT1 (0.39) | NR3C2CNR1CNR2ALDH1A1KDM4E | |
| SCHEMBL13423886 | 0.85 | CNR1 (0.36) | CNR1CNR2ALDH1A1 | |
| SCHEMBL13423876 | 0.85 | ALDH1A1 (0.38) | NR3C2CNR1CNR2ALDH1A1C5AR1 | |
| SCHEMBL13423957 | 0.83 | UCHL1 (0.34) | NR3C2CNR1CNR2SLC5A1C5AR1 | |
| SCHEMBL13423885 | 0.83 | CNR1 (0.35) | CNR1CNR2ALDH1A1C5AR1 | |
| SCHEMBL13423960 | 0.83 | C5AR1 (0.38) | NR3C2CNR1CNR2SLC5A1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2350084-B1 | TETRA-AZA-HETEROCYCLES AS PHOSPHATIDYLINOSITOL-3-KINASES (PI3-KINASES) INHIBITOR | BOEHRINGER INGELHEIM INT (DE) | 2015-06-24 | — | — | EP | disclosed |
| US-8653097-B2 | Tetra-aza-heterocycles as phosphatidylinositol-3-kinases (P13-kinases) inhibitor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-18 | — | — | US | disclosed |
| US-8653097-B2 | Tetra-aza-heterocycles as phosphatidylinositol-3-kinases (P13-kinases) inhibitor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-18 | — | — | US | disclosed |
| US-20110312940-A1 | TETRA-AZA-HETEROCYCLES AS PHOSPHATIDYLINOSITOL-3-KINASES (P13-KINASES) INHIBITOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | disclosed |
| US-20110312940-A1 | TETRA-AZA-HETEROCYCLES AS PHOSPHATIDYLINOSITOL-3-KINASES (P13-KINASES) INHIBITOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | disclosed |
| WO-2010043676-A1 | TETRA-AZA-HETEROCYCLES AS PHOSPHATIDYLINOSITOL-3-KINASES (PI3-KINASES) INHIBITOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312940-A1 | TETRA-AZA-HETEROCYCLES AS PHOSPHATIDYLINOSITOL-3-KINASES (P13-KINASES) INHIBITOR | CCNK, CDK1, CDKN1A | NR3C2 1291/4885CNR1 2454/4885CNR2 3835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.